Analysts Offer Insights on Healthcare Companies: Intercept Pharma (NASDAQ: ICPT) and Lexicon Pharmaceuticals (NASDAQ: LXRX)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Intercept Pharma (NASDAQ: ICPT) and Lexicon Pharmaceuticals (NASDAQ: LXRX) with bullish sentiments.

Intercept Pharma (NASDAQ: ICPT)

Cowen & Co. analyst Ritu Baral reiterated a Buy rating on Intercept Pharma (NASDAQ: ICPT) today and set a price target of $225. The company’s shares opened today at $116.98.

Baral commented:

“We hosted a group investor lunch recently with ICPT management.”

According to TipRanks.com, Baral is a 5-star analyst with an average return of 10.4% and a 43.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Global Blood Therapeutics, and Protalix Biotherapeutics.

Currently, the analyst consensus on Intercept Pharma is Moderate Buy and the average price target is $182.57, representing a 56.1% upside.

In a report issued on June 1, Credit Suisse also reiterated a Buy rating on the stock with a $201 price target.
Lexicon Pharmaceuticals (NASDAQ: LXRX)

In a report released today, Alan Carr from Needham reiterated a Buy rating on Lexicon Pharmaceuticals (NASDAQ: LXRX), with a price target of $21. The company’s shares opened today at $16.38.

Carr observed:

“Lexicon presented additional data from Phase 3 sotagliflozin Type 1 Diabetes (T1D) program and hosted investor event at ADA mtg. New data included Phase 3 ‘net benefit’ analysis demonstrating statistically significant improvements in proportion of pts experiencing reduction in A1C (blood glucose) w/ no severe hypoglycemia or Diabetic Ketoacidosis (DKA). KOL expectations for SGL T inhibitor use in T1D are high and first-to-market cited as key advantage for sotagliflozin. KOLs believe long-term market share will be driven by extent of A1C reduction and safety profile. Mgmt reiterated guidance for collaborator Sanofi NDA submission in T1D 1Q18, pointing to FDA approval in early 2019. Competitors are likely ~1yr behind.”

According to TipRanks.com, Carr is a 4-star analyst with an average return of 8.7% and a 44.8% success rate. Carr covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences Inc, Aquinox Pharmaceuticals, and ACADIA Pharmaceuticals.

Lexicon Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $28.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.